USD
$0.00
(0.00%
)At Close (As of Oct 13, 2025)
$741.10M
Market Cap
-
P/E Ratio
-0.89
EPS
$16.76
52 Week High
$5.63
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $126M |
Total Revenue | $131M |
Cost Of Revenue | $5.3M |
Costof Goods And Services Sold | $5.3M |
Operating Income | -$217M |
Selling General And Administrative | $32M |
Research And Development | $228M |
Operating Expenses | $343M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | $20M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2M |
Income Before Tax | -$88M |
Income Tax Expense | -$7.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$95M |
Comprehensive Income Net Of Tax | - |
Ebit | -$219M |
Ebitda | -$217M |
Net Income | -$95M |
Field | Value (USD) |
---|---|
Total Assets | $583M |
Total Current Assets | $562M |
Cash And Cash Equivalents At Carrying Value | $125M |
Cash And Short Term Investments | $125M |
Inventory | $3.3M |
Current Net Receivables | $14M |
Total Non Current Assets | $20M |
Property Plant Equipment | $4.7M |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $16M |
Intangible Assets Excluding Goodwill | $16M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $407M |
Other Current Assets | $13M |
Other Non Current Assets | - |
Total Liabilities | $80M |
Total Current Liabilities | $73M |
Current Accounts Payable | $3.3M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $20K |
Total Non Current Liabilities | $6.6M |
Capital Lease Obligations | $2.6M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $2.6M |
Other Current Liabilities | $69M |
Other Non Current Liabilities | $761K |
Total Shareholder Equity | $503M |
Treasury Stock | - |
Retained Earnings | -$554M |
Common Stock | $10K |
Common Stock Shares Outstanding | $94M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$78M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $2M |
Capital Expenditures | $2.2M |
Change In Receivables | - |
Change In Inventory | -$3.2M |
Profit Loss | - |
Cashflow From Investment | -$231M |
Cashflow From Financing | $203M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $25M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$95M |
Field | Value (USD) |
---|---|
Gross Profit | $126M |
Total Revenue | $131M |
Cost Of Revenue | $5.3M |
Costof Goods And Services Sold | $5.3M |
Operating Income | -$217M |
Selling General And Administrative | $32M |
Research And Development | $228M |
Operating Expenses | $343M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | $20M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2M |
Income Before Tax | -$88M |
Income Tax Expense | -$7.1M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$95M |
Comprehensive Income Net Of Tax | - |
Ebit | -$219M |
Ebitda | -$217M |
Net Income | -$95M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted therapies for patients with genetically defined cancers. With a robust pipeline aimed at addressing significant unmet medical needs, Day One is dedicated to advancing precision medicine that transforms patient outcomes. The company's innovative approach leverages cutting-edge science to deliver therapies that specifically target genetic mutations in tumors, positioning it as a key player in the rapidly evolving oncology landscape.